Prostate Cancer
Conference Coverage
High-dose RT and long-term ADT improve survival in high-risk prostate cancer
These results are “practice-affirming for many,” according to an expert commenting on the new findings.
News
Functional Outcomes in Localized Prostate Cancer: Treatment Choice, Time, Prognosis All Matter
New study sheds light on quality of life effects related to disease severity and treatment choice.
News
Prostate Risks Similar for Testosterone Therapy and Placebo
Uncertainty and concern exist about a link between prostate cancer risk and testosterone levels.
News
CMS Okays Payment for Novel AI Prostate Test
The test improves risk stratification or prognostication over standard clinical and pathologic tools, says expert.
News
Testosterone Replacement Therapy and Prostate Cancer Risk
New study suggests testosterone replacement therapy does not increase prostate cancer risk in men with hypogonadism.
News
Side Effects of Local Treatment for Advanced Prostate Cancer May Linger for Years
A new study compared long-term side effects in men with advanced prostate cancer who received initial local treatment with those who opted for...
Latest News
Active Surveillance for Low-Risk PCa: Sprint or Marathon?
For some men, the strategy can prove to be short-lived, perhaps 5 years or less , or a life-long approach lasting until the man dies from another...
Latest News
What the first authorized DNA cancer risk test can and can’t tell you
The test can identify genetic variants that increase an individual’s risk of certain cancers and help identify potential cancer-related hereditary...
Conference Coverage
Short-course SBRT: Standard of care in prostate cancer?
Stereotactic body radiation therapy delivered in five fractions provided similar 5-year disease control as conventional, higher-dose external-beam...
News
Cost concerns lead to cancer treatment delays, nonadherence
Hospital-based financial navigators may help cancer patients negotiate the intricacies of insurance coverage, experts suggest.